We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Beleaguered Indian generics maker Wockhardt said Tuesday it will recall all remaining batches of 12 to 15 products from the U.S. that were manufactured at its Waluj and Chikalthana, India, plants, due to quality concerns. Read More
Nearly three years after generics giant Mylan accused Warner Chilcott and Mayne Pharmaceuticals of “product hopping” with their acne medication Doryx, a federal judge has dismissed the case, ruling in favor of the brandmakers. Read More
Particulates continue to be a major cause of recalled injectables, with Mylan on Thursday recalling eight lots of four drugs after foreign matter was found during quality control tests. Read More
The HHS Office of Inspector is urging Congress to rewrite the Medicare Part D in the Social Security Act to allow for collection of additional rebates from drug companies. Read More
Reckitt Benckiser is voluntarily recalling 1.5 million units of four varieties of its Mucinex liquid cold medicines nationwide because the back labels may not show they contain acetaminophen and other active ingredients. Read More
The Medicare program would have saved $251 million on DME infusion drugs over an 18-month period if the Centers for Medicare & Medicaid Services had stopped paying wholesale prices set more than a decade ago, the HHS Office of Inspector General says. Read More
Israeli pharma giant Teva is offering $43 billion to acquire rival generics maker Mylan, following weeks of widespread speculation about a possible deal, but the deal may not go down easy. Read More